NMN and Aging: What We Know and What We Don't

Four separate questions, often collapsed into one

"NMN and aging" actually asks four distinct questions that require different kinds of evidence, and this page keeps them apart: (A) does NAD+ decline with age, and does that matter biologically? (B) what happens when NMN is given to animals? (C) what happens when NMN is given to humans? (D) is there any evidence NMN extends human lifespan? These are covered, respectively, on Why Does NAD+ Decline With Age? (A), briefly below (B), on NMN Human Clinical Trials in full (C), and directly here (D). Treating a "yes" to one of these as a "yes" to all four is the single most common error in NMN marketing, and this page exists to prevent it.

A. NAD+ biology and aging

NAD+-related measurements decline with age in multiple human studies, including a direct measurement of the plasma NAD+ metabolome across ages 20–87.[1] The enzymes that consume NAD+ — CD38, PARPs — are separately documented to change with age, primarily in animal models, discussed in full on NAD+ and CD38. This is established descriptive biology: NAD+-related markers correlate with age. It is not, by itself, evidence that raising NAD+ from outside the body slows, stops, or reverses the aging process.

B. Animal NMN research

Preclinical studies in mice — genetic sirtuin overexpression, CD38 knockout, and direct NMN administration — report effects on NAD+ levels, tissue function, and in some specific genetic models, lifespan.[2][3] These are real, peer-reviewed findings, and they are why NMN is studied at all. They are also, without exception, findings in animals — genetically engineered or otherwise — under laboratory conditions, not evidence about adult humans taking an oral supplement. See NAD+ and Sirtuins and NAD+ and CD38 for this preclinical evidence in full, explicitly labeled as such.

C. Human NMN trials

Published human NMN trials have measured blood NAD+, specific physiological outcomes (insulin signaling, walking speed, blood pressure), and short-term tolerability — never a validated biological-age clock, and never lifespan itself, for the obvious reason that a human lifespan trial is not practically feasible on any timescale relevant to a supplement market. See NMN Human Clinical Trials: Complete Evidence Review for the complete trial-by-trial breakdown, including which findings were positive, which were null, and which were secondary rather than primary outcomes.

D. Lifespan and longevity: the evidence that does not exist

There is currently no human evidence demonstrating that NMN extends lifespan. No trial has run long enough, in a large enough population, with mortality or a validated aging-clock endpoint, to test that question — and none of the trials reviewed on this hub attempted to. Terms like "anti-aging," "reverses aging," "slows aging," and "longevity supplement" describe a specific, demonstrated human outcome that has not been shown for NMN. This hub does not use them as established claims about NMN.

On biological-age clocks and aging biomarkers

Where a trial has measured an aging-related biomarker — for example, one dose-ranging trial reported that a computed "biological age" measure increased in the placebo group but stayed unchanged in NMN-treated groups over 60 days[4] — it is essential to be precise about what that means. A composite biological-age score is a statistical estimate built from selected blood biomarkers; it is not a measurement of aging itself, has not been validated against actual lifespan or age-related disease outcomes in this context, and "did not increase" over 60 days is a much narrower claim than "aging slowed." This hub reports what was actually measured rather than translating a biomarker result into a broader claim the study did not make.

Related reading

For the underlying biochemistry, see Why Does NAD+ Decline With Age?, NAD+ and CD38, and NAD+ and Sirtuins. For the complete human trial record, see NMN Human Clinical Trials.